the aid library

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Six I’s HIV/TB Communication and Advocacy Toolkit

AIDS and Rights Alliance for Southern Africa (ARASA) (2017) CC

Please download the complete toolkit directly from the website (large size: 24 MB)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Innovation in deinstitutionalization: a WHO expert survey

World Health Organization WHO (2014) C_WHO

Based on the survey, five principles for deinstitutionalization were identified: community-based services must be in place; the health workforce must be committed to change; political support at the highest and broadest levels is crucial; timing is key; and additional financial resources are needed. ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Prof. G. N. Lule, Dr. B. Nyawira Gastroenterology Society of Kenya , Republic of Keny (2015) C1

Brief, structured psychological treatment

World Health Organization WHO (2012) C_WHO

Q 3: Is brief, structured psychological treatment in non-specialist health care settings better (more effective than/as safe as) than treatment as usual in people with depressive episode/disorder?

Essential Package of Health Services (EPHS). Secondary & Tertiary Care: The District, County & National Health Systems (Liberia)
recommended

Ministry of Health & Social Welfare, Liberia (2011) C1

Essential Drug list on page 36!!

Ghana National Health Policy: Creating Wealth through Health

Ministry of Health Ghana; (2007) C1

Recommendations for Conducting Ethical Mental Health and Psychosocial Research in Emergency Settings

Inter-Agency Standing Committee (IASC) Reference Group for Mental Health and Psychosocial Support in Emergency Settings (2014) C2

Epidemic meningitis surveillance in the African meningitis belt

World Health Organization WHO (2014) C_WHO

This document is intended to serve as a reference for national public health policy-makers. It outlines the scope of potential meningitis surveillance strategies that make it possible to obtain the data required for epidemic detection, monitoring of epidemiological and microbiological trends, evalua ... more

Tuberkulosescreening bei asylsuchenden Kindern und Jugendlichen < 15 Jahren in Deutschland

Nicole Ritz, Folke Brinkmann, Cornelia Feiterna-Sperling. et al. Springer (2015) C2

Stellungnahme der Arbeitsgruppe AWMFLeitlinie Tuberkulose im Kindes- und Jugendalter: Diagnostik, Prävention und Therapie unter Federführung der Deutschen Gesellschaft für Pädiatrische Infektiologie. Monatsschr Kinderheilkd 2015 · 163:1287–1292 DOI 10.1007/s00112-015-0007-5 © Deutsche Gesel ... more

Panduan Penanganan Kanker Kandung Kemih Tipe Urotelial

Umbas, R., S. Hardjowijoto, C.A. Mochtar, et al., Indonesian Urological Association (2014) C1

Guidelines for Therapy and Management of Urothelial Urinary Bladder Cancer

Lineamientos para el Manejo Clínico y Operativo de la Tuberculosis Drogorresistente

J. A. Caminero, A. Van Deun, P. I. Fujiwara, et. al Unión Internacional Contra la Tuberculosis y Enfermedades Respiratorias (2013)

Tuberculosis prevention, care and control A practical directory of new advances

Stop TB Partnership; World Health Organization ; USAID (2011) C_WHO

CONSENSUS DOCUMENT FOR MANAGEMENT OF GASTRIC CANCER

Indian Council of Medical Research (ICMR) (2014) C1

Full document available: https://www.icmr.nic.in/sites/default/files/guidelines/Gastric%20Cancer%20Final%20pdf%20for%20farrow_0.pdf | Prepared as an outcome of ICMR Subcommittee on Gastric Cancer | Coordinated by Division of Non Communicable Diseases | This Consensus Document on Management of Gastri ... more

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I ... more

The global doctor

Willott C et al. UCL Institute for Global Health and Development Education Research Centre, Institute of Education (2012) C2

This report explores the reasons why global health is critical to medicine and what this means for medical education. It argues that an understanding of global health is important for all students and practicing doctors, rather than being an ‘add-on’ or ‘option’ for specialization.